Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RIGL
RIGL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RIGL News
Rigel Pharmaceuticals Appoints New Board Member
Feb 03 2026
PRnewswire
Rigel Pharmaceuticals Projects 2026 Revenue of $275 to $290 Million
Jan 12 2026
PRnewswire
Rigel Pharmaceuticals Grants 24,775 Stock Options to Attract Talent
Jan 09 2026
PRnewswire
Rigel Pharmaceuticals Grants 24,775 Stock Options to New Employees
Jan 09 2026
Newsfilter
Onco360 Selected as Limited Distribution Partner for Rigel's TAVALISSE, GAVRETO, and REZLIDHIA
Jan 07 2026
Globenewswire
Rigel Pharmaceuticals CEO to Present Company Overview at 44th Annual J.P. Morgan Healthcare Conference
Jan 07 2026
PRnewswire
Rigel Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 07 2026
Newsfilter
Rigel's R289 Demonstrates Potential for RBC Transfusion Independence in Phase 1b Trial for Lower-Risk MDS
Dec 08 2025
NASDAQ.COM
Rigel Pharmaceuticals Reports Preliminary Efficacy of R289 in Lower-Risk MDS Patients
Dec 07 2025
Newsfilter
Rigel Pharmaceuticals Updates R289 Clinical Data, Anticipates Phase 2 Dose Selection in 2026
Dec 07 2025
PRnewswire
Rigel Pharmaceuticals (RIGL) Shows Strong Momentum: Is It a Good Investment?
Dec 05 2025
NASDAQ.COM
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 26 2025
PRnewswire
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Nov 19 2025
NASDAQ.COM
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Nov 17 2025
PRnewswire
Rigel to Present at the Jefferies Global Healthcare Conference in London
Nov 12 2025
PRnewswire
Rising Earnings Projections Indicate Potential Growth for Rigel (RIGL) Stock
Nov 06 2025
NASDAQ.COM
Show More News
